Summary
pressin [41, increased levels of immunoreactive P-endorphin (IR-P-EP) in pituitary neurointermediate lobe (N-IL) and decreased plasma levels of IR-PEP [51. The secretion of these hormones is considered to be under tonic dopaminergic control; studies in vitro have shown that dopamine suppresses the release of vasopressin and neurophysin from the pituitary [6] . The dopaminergic agonist, bromocriptine, produces a rapid, profound fall in blood pressure of SHR [61; other antihypertensive agents, e.g. captopril, have been shown to reduce the urinary output of vasopressin in SHR [71. As opioids are hypotensive agents, and P-endorphin release may be impaired in SHR, we compared the effects of morphine and naloxone on blood pressure of SHR and NT-WKY rats, and studied the effects of bromocriptine on blood pressure and tissue P-endorphin levels.
Methods
Female SHR (n = 9) and NT-WKY rats (n = 9) were anaesthetized with Inactin, which has no depressor effects in rats [81; in each rat the left jugular vein and carotid artery were cannulated. Pulsatile and mean arterial pressure were recorded continuously on a Grass polygraph with Statham p 23 Db pressure transducers. After 30 min, morphine (2 mg/kg) was injected intravenously, followed 1 h later by naloxone (1 mg/kg); blood pressure was monitored for a further hour. 
Results
Morphine (2 mg/kg) given intravenously significantly lowered mean blood pressure of SHR (n = 9) from 176 f 6 to 117 11 mmHg (mean ? SEM) and of NT-WKY rats (n = 9) from 142 + 3 to 111 f 5 mmHg (P < 0-005). These falls in blood pressure were 34% of control values for SHR and 22% of control values for NT-WKY rats. Intravenous naloxone (1 mg/kg) restored blood pressure of SHR to 177 & 4 mmHg and of NT-WKY rats to 149 5 6 mmHg: these values were not significantly different from those from the two groups during their control, pre-morphine period.
Blood pressures of the bromocriptine-treated group of SHR fell significantly from 153 f 4 to 118 f 4 mmHg (F7,49 = 3.8, P < 0.005); blood pressures of the vehicle-treated group of SHR did not change significantly (163 f 4 to 145 6 mmHg, F,,,, = 1.4, P > 0.05). Bromocriptinetreated SHR had significantly (P < 0.05) lower levels of N-IL IR-PEP than vehicle-treated SHR (Fig. 1) ; no difference in anterior pituitary IR-PEP levels was found between treatments. Though the mean level of plasma IR-PEP in bromocriptine-tested rats was double that of the vehicle-tested group, the difference was not statis- 
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Discussion
The results presented here show that an exogenous opiate (morphine) lowers blood pressure of SHR more than that of NR-WKY rats both absolutely and relatively, and that this hypotensive action was completely reversed by a modest dose of naloxone. As previously reported [ 51, differences in immunoreactive P-endorphin levels in the neuro-intermediate lobe and plasma of SHR, compared with NT-WKY rats, are consistent with a role of endogenous opioids in the elevated blood pressure of SHR. The elevated neuro-intermediate lobe content of immunoreactive P-endorphin supports the dopaminergic defect postulated [61 in this model of hypertension. The lack of statistical significance for the increased mean plasma level of P-endorphin in the bromocriptine-treated SHR, compared with the vehicle-treated SHR, warrants further comment. The dose of bromocriptine in this group was low (22 pg/h) because of the low solubility of the drug. Higher doses, accordingly, may provide a more consistent effect on plasma levels of immunoreactive P-endorphin; this possibility is at present being investigated. The postulated dopaminergic defect in SHR is further supported by observations that hypothalamic dopamine levels are decreased in SHR compared with NT-WKY rats [lo] . Abnormalities in prolactin, thyrotrophic hormone, vasopressin, and P-endorphin, together with the hypotensive response to SHR to a dopamine agonist, also seem consistent with a dopaminergic defect. The reports, however, that agents such as vasopressin antiserum I111 will lower blood pressure of SHR to normal raise a conceptual difficulty. If the SHR is defective in tubero-infundibular and tuberohypophyseal dopamine control of the release of several pituitary hormones, it is difficult to understand how correction of only one reduces SHR blood pressure to normal.
